Related Experiment Videos
Arrhythmogenic right ventricular dysplasia/cardiomyopathy.
Victor A Ferrari1, Craig H Scott, Cristina Basso
1Department of Medicine, Cardiovascular Medicine Division, University of Pennsylvania School of Medicine, 9014 E. Gates Pavilion, 3400 Spruce Street, Philadelphia, PA 19014, USA. ferrariv@mail.med.upenn.edu
Current Cardiology Reports
|December 22, 2004
Summary
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is a key cause of sudden death in young athletes. Cardiac MRI shows promise for diagnosis, but resolution and reader variability remain challenges.
Area of Science:
- Cardiology
- Medical Imaging
- Genetics
Background:
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is a significant cause of sudden cardiac death in young individuals, especially athletes.
- Recent advancements in cardiac MRI aim to enhance the noninvasive diagnosis of ARVC.
Purpose of the Study:
- To evaluate the diagnostic accuracy of current cardiac MRI techniques for arrhythmogenic right ventricular dysplasia/cardiomyopathy.
- To identify limitations and future directions for improving ARVC diagnosis using cardiac MRI.
Main Methods:
- Utilized advanced cardiac MRI sequences, including steady-state free precession and rapid fat saturation techniques.
- Conducted formal diagnostic accuracy testing with a diverse group of readers.
Main Results:
- Cardiac MRI examinations were comprehensive and well-tolerated by patients.
- Despite technical improvements, limited spatial resolution and interobserver variability were identified as key challenges.
- Current methods have not yet achieved successful widespread implementation due to these limitations.
Conclusions:
- Cardiac MRI has evolved significantly for ARVC diagnosis, offering comprehensive examinations.
- Further advancements, such as high-field 3 Tesla imaging and viability imaging, are needed to overcome current limitations and improve diagnostic accuracy.
- Addressing spatial resolution and interobserver variability is crucial for clinical adoption.